Francisco Gual-Capllonch

Dr. Francisco Gual-Capllonch


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OAOmar Abdul-Jawad Altisent
Omar Abdul-Jawad Altisent
RBRimantas Benetis
Rimantas Benetis
EREgle Rumbinaite
Egle Rumbinaite
VMVaida Mizarien
Vaida Mizarien
PCPau Codina
Pau Codina
RPRishi Puri
Rishi Puri
Severe tricuspid regurgitation remains a challenging heart-valve disease to effectively treat with high morbidity and mortality at mid-term. Currently guideline-directed medical treatment is limited to escalating dose of diuretics, and the rationale and timing of open-heart surgery remains controversial. Emerging percutaneous therapies for severe tricuspid regurgitation continue to show promising results in early feasibility studies. However, randomized trial data is lacking. Additionally, many patients are deemed unsuitable for these emerging therapies due to anatomical or imaging constraints. Given the technical simplicity of the bicaval valve implantation (CAVI) technique compared to other transcatheter devices, CAVI is postulated as a suitable alternative for a wide variety of patients affected with severe+ tricuspid regurgitation. In this review we illustrate the current evidence and ongoing uncertainties of CAVI, focusing on the novel CAVI-specific devices.

1 January 2021 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
FGFrancisco Gual-Capllonch
Francisco Gual-Capllonch
GCGermán Cediel
Germán Cediel
EFElena Ferrer
Elena Ferrer
ATAlbert Teis
Albert Teis
GJGladys Juncà
Gladys Juncà
ABAntoni Bayes-Genis
Antoni Bayes-Genis

13 June 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
FGFrancisco Gual-Capllonch
Francisco Gual-Capllonch
JIJosé Ignacio Sáenz de Ibarra
José Ignacio Sáenz de Ibarra
ABAntoni Bayés-Genís
Antoni Bayés-Genís
VDVictoria Delgado
Victoria Delgado
Atrial functional regurgitation is caused by atrioventricular annulus dilation, with normal leaflets and ventricular dimensions and function within the normal range. Its occurrence, in both mitral and tricuspid valves, implies a worse prognosis due to the hemodynamic derangement they produce, but also constitutes a marker of greater comorbidity and more advanced disease. Predisposing conditions for these heart valve dysfunctions are mainly atrial fibrillation and heart failure with preserved ejection fraction. However, other factors like female sex also may be involved and influence their incidence, especially for atrial tricuspid regurgitation. In the present review, we analyze sex differences in the reported prevalence of atrial mitral and tricuspid regurgitation, and suggest possible mechanisms involved. Finally, we underline potential therapeutic and preventive strategies to reduce the burden of these heart valve disorders and discuss research gaps.

23 August 2018 in Echocardiography
Verified
Journal Article
Closed access
PDF file
FGFrancisco Gual-Capllonch
Francisco Gual-Capllonch
ATAlbert Teis
Albert Teis
EFElena Ferrer
Elena Ferrer
JNJulio Núñez
Julio Núñez
NVNuria Vallejo
Nuria Vallejo
ABAntoni Bayes
Antoni Bayes

29 November 2021 in Echocardiography
Verified
Journal Article
Closed access
PDF file
FGFrancisco Gual-Capllonch
Francisco Gual-Capllonch
GCGermán Cediel
Germán Cediel
ATAlbert Teis
Albert Teis
EFElena Ferrer‐Sistach
Elena Ferrer‐Sistach
ABAndrea Borrellas
Andrea Borrellas
ABAntoni Bayes‐Genis
Antoni Bayes‐Genis

24 February 2021 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
FGFrancisco Gual-Capllonch
Francisco Gual-Capllonch
JLJosep Lupón
Josep Lupón
IBIoana Bancu
Ioana Bancu
FGFredzzia Graterol
Fredzzia Graterol
EFElena Ferrer-Sistach
Elena Ferrer-Sistach
ABAntoni Bayes
Antoni Bayes